Phase I-II trial of gallium nitrate for advanced hypernephroma.
Gallium nitrate in doses of 100-200 mg/m2/day was continuously infused for 7 consecutive days to 12 patients with advanced hypernephroma. Since nephrotoxicity was moderate and no objective tumor response was observed in ten adequately treated cases, further trials with this agent for hypernephroma are unwarrented.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005708:Gallium / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D005708:Gallium; C027235:gallium nitrate